AGP Picks
View all

Pegasys Copegus combination pack market seen growing at slower pace through 2035

Nov. 9, 2026
Pegasys Copegus combination pack market seen growing at slower pace through 2035
By AI, Created 15:45 UTC, Nov 09, 2026, AGP -

The Pegasys Copegus combination pack market is expected to keep expanding through 2035, but at a slower pace as newer antivirals take share. Demand will be driven mainly by resource-limited regions and patients still eligible for interferon-based therapy, according to The Business Research Company.

Why it matters: - The Pegasys Copegus combination pack remains a treatment option for chronic hepatitis C, especially where lower-cost therapies still matter. - Market demand is expected to persist even as direct-acting antivirals become the preferred standard in many settings. - The segment offers a view into how older hepatitis C therapies are being retained for specific patient groups and markets.

What happened: - The Business Research Company released its Pegasys Copegus Combination Global Market Report 2026 – Market Size, Trends, And Forecast 2026-2035 on Nov. 9, 2026. - The report says the market has grown historically on the back of widespread clinical adoption, reimbursement support, standardized treatment protocols, high hepatitis C burden and hospital-channel availability. - The report projects continued growth through 2035, but at a more restrained pace. - The analysis includes regional coverage for Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - The report also adds market attractiveness scoring, TAM analysis, company scoring matrices, Excel-based forecasting dashboards, hotspot infographics and updated graphics.

The details: - Pegasys combines peginterferon alfa-2a, an injectable immune-system booster, with Copegus, an oral antiviral that blocks viral replication. - The combination pack is used for chronic hepatitis C and is intended to improve the chance of sustained virological response. - The report says future demand will come mainly from resource-limited regions and patients who remain eligible for interferon therapy. - The report expects volumes to decline as newer antiviral drugs gain share. - It says affordable treatment options, monitoring of long-term outcomes and optimization of fixed-dose regimens will help sustain activity. - The report identifies steady use of combination packs, growing preference for direct-acting antivirals and a focus on SVR in select cases as key trends. - The report says rising global chronic hepatitis C prevalence is a major growth driver. - Hepatitis C can lead to cirrhosis and liver cancer. - The report cites injectable drug use, unsafe medical practices and unsafe blood transfusions as contributors to infection spread. - An August 2023 American Liver Foundation report said 2.7 million to 3.9 million people in the U.S. live with chronic hepatitis C, with about 17,000 new cases annually. - The report says expanding healthcare infrastructure supports wider treatment distribution and use. - A 2023 American Health Care Association report said U.S. hospitals increased from 5,129 in 2022 to 6,120 in 2023. - The report says growing hepatitis C clinical trials support market expansion by validating efficacy and outcomes. - The American Society of Gene and Cell Therapy reported a 25% increase in gene therapy trials in the second quarter of 2024, with 76 new studies launched.

Between the lines: - The market story is shifting from growth driven by broad hepatitis C treatment use to a narrower niche focused on affordability, access and remaining eligible patients. - North America’s lead in 2025 suggests mature infrastructure and disease burden still support demand, while Asia-Pacific’s faster forecast growth points to where volume gains may still be available. - The report’s emphasis on SVR shows that clinical value remains tied to specific treatment goals, even as newer drugs reshape the market.

What's next: - The report expects the combination pack to keep selling, but at lower volume than earlier years. - Resource-limited markets and patients unable to use newer antivirals are likely to remain the main demand base. - Asia-Pacific is expected to post the fastest growth rate during the forecast period. - The Business Research Company is offering a free sample and full report download via the company’s sample request page and the full market report.

The bottom line: - Pegasys Copegus is no longer a high-growth hepatitis C market, but it still has a defined role where affordability, access and older treatment protocols remain important.

Disclaimer: This article was produced by AGP Wire with the assistance of artificial intelligence based on original source content and has been refined to improve clarity, structure, and readability. This content is provided on an “as is” basis. While care has been taken in its preparation, it may contain inaccuracies or omissions, and readers should consult the original source and independently verify key information where appropriate. This content is for informational purposes only and does not constitute legal, financial, investment, or other professional advice.

Sign up for:

Africa News Guide

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.

Share this page:

Advanced Search Options

Search for:

Search scope:

Type:

Search in:

Date range:

The last

Sort by:

Sign up for:

Africa News Guide

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.